Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events | British Journal of Cancer
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial - The Lancet Oncology
New drugs
Axitinib dose-dependently induces apoptosis in the renal cell carcinoma... | Download Scientific Diagram
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study | BMC Cancer | Full Text
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma - ScienceDirect
Prior Sunitinib Duration Affects Second-Line RCC Therapy Outcomes - Renal and Urology News
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial - The Lancet Oncology
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results | Journal of Translational Medicine | Full Text
Table 1 from Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma | Semantic Scholar
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events | British Journal of Cancer
BACKGROUND OBJECTIVE METHODS RESULTS LIMITATIONS CONCLUSIONS
Axitinib inhibits RCC cell viability in a dose and time-dependent... | Download Scientific Diagram
Clinical criteria for axitinib dose adjustment. (A) Criteria for... | Download Scientific Diagram
Axitinib for the first line therapy of renal cancer: failure of a trial or failure of a strategy? - Jardim - Translational Cancer Research
Individualized dosing with axitinib: rationale and practical guidance | Future Oncology
Axinix (Axitinib) 5 MG - Emergency Drug - Buy Medicine Online Low Price
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results | Journal of Translational Medicine | Full Text
Approved for use in:
Individualized dosing with axitinib: rationale and practical guidance | Future Oncology
ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426
Inlyta Full Prescribing Information, Dosage & Side Effects | MIMS Indonesia
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study | BMC Cancer | Full Text
